Status:
COMPLETED
Real-world Evaluation of JBA GlucoTrojan With Reducose® on Glycemic Response
Lead Sponsor:
Tastermonial Inc
Collaborating Sponsors:
WCG clinical
Affordable Quality Pharmaceuticals
Conditions:
Food Habits
Eligibility:
All Genders
21-75 years
Phase:
NA
Brief Summary
The project is focused on evaluating the real-world efficacy of JBA GlucoTrojan, a powdered supplement sachet containing Reducose, a natural water extract of White Mulberry Leaf, which has been scient...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Consent to study protocol
- BMI: 18.5 to 29.9 kg/m2
- 21 to 75 years old
- Exclusion criteria:
- Physician-diagnosed T1D and insulin-dependent T2D
- Taking medications that modulate blood glucose response or control blood pressure other than Metformin
- An underlying health condition that warrants non-participation
- Individuals who are pregnant
- Any other dietary restrictions that prevent them from consuming study foods
- Unable to follow remote guidance via the Internet or smartphone
- Unable to follow controlled diet instructions
- Unable to use a CGM (Continuous Glucose Monitoring Devices)
Exclusion
Key Trial Info
Start Date :
April 4 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 4 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06509204
Start Date
April 4 2023
End Date
June 4 2023
Last Update
July 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tastermonial
Cupertino, California, United States, 95014